Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Blueprint Medicines Corp (BPMC) USD0.001

Sell:$95.51 Buy:$95.94 Change: $5.77 (5.84%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$95.51
Buy:$95.94
Change: $5.77 (5.84%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:$95.51
Buy:$95.94
Change: $5.77 (5.84%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Contact details

Address:
45 Sidney St
CAMBRIDGE
02139-4133
United States
Telephone:
+1 (617) 3747580
Website:
www.blueprintmedicines.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BPMC
ISIN:
US09627Y1091
Market cap:
$5.56 billion
Shares in issue:
57.96 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel Lynch
    Independent Chairman of the Board
  • Fouad Namouni
    President, Research & Development
  • Jeffrey Albers
    Chief Executive Officer, Director
  • Michael Landsittel
    Chief Financial Officer
  • Kathryn Haviland
    Chief Operating Officer
  • Debra Durso-Bumpus
    Chief Human Resource Officer
  • Anthony Boral
    Executive Vice President - Clinical Development
  • Christopher Murray
    Senior Vice President, Technical Operations
  • Marion Dorsch
    Chief Scientific Officer
  • Tracey McCain
    Chief Legal Officer, Chief Compliance Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.